PT1484033E - Composições poliméricas líquidas para libertação controlada de substâncias bioactivas - Google Patents

Composições poliméricas líquidas para libertação controlada de substâncias bioactivas Download PDF

Info

Publication number: PT1484033E
Authority: PT; Portugal
Prior art keywords: polymer; liquid; composition; quot; lactide
Prior art date: 1998-03-19

Application number

PT04076699T

Other languages

English (en)

Portuguese (pt)

Inventor

Rey T Chern

Joel R Zingerman

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-19

Filing date

1999-03-18

Publication date

2011-04-21

1999-03-18 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2011-04-21 Publication of PT1484033E publication Critical patent/PT1484033E/pt

Links

239000000203 mixture Substances 0.000 title claims abstract description 129
239000007788 liquid Substances 0.000 title claims abstract description 59
238000013270 controlled release Methods 0.000 title claims description 16
230000000975 bioactive effect Effects 0.000 title abstract description 52
239000000126 substance Substances 0.000 title abstract description 35
239000002904 solvent Substances 0.000 claims abstract description 71
239000003814 drug Substances 0.000 claims abstract description 18
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims abstract description 5
229920000642 polymer Polymers 0.000 claims description 84
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 26
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical group CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 26
WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 19
229960002346 eprinomectin Drugs 0.000 claims description 17
238000000034 method Methods 0.000 claims description 15
239000001087 glyceryl triacetate Substances 0.000 claims description 13
235000013773 glyceryl triacetate Nutrition 0.000 claims description 13
229960002622 triacetin Drugs 0.000 claims description 13
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 7
241000283690 Bos taurus Species 0.000 claims description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
241000282465 Canis Species 0.000 claims 1
230000002209 hydrophobic effect Effects 0.000 abstract description 18
229920001577 copolymer Polymers 0.000 abstract description 14
229940079593 drug Drugs 0.000 abstract description 14
238000009472 formulation Methods 0.000 description 31
241001465754 Metazoa Species 0.000 description 27
239000013543 active substance Substances 0.000 description 14
239000010408 film Substances 0.000 description 14
238000011065 in-situ storage Methods 0.000 description 14
239000007787 solid Substances 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
230000007774 longterm Effects 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
-1 alkyl ketones Chemical class 0.000 description 10
230000036470 plasma concentration Effects 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
239000007943 implant Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
230000002459 sustained effect Effects 0.000 description 8
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 7
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
239000012867 bioactive agent Substances 0.000 description 7
229960002418 ivermectin Drugs 0.000 description 7
239000012669 liquid formulation Substances 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
238000001647 drug administration Methods 0.000 description 5
239000007972 injectable composition Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000011148 porous material Substances 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
206010061217 Infestation Diseases 0.000 description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
239000012530 fluid Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
229940074076 glycerol formal Drugs 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
229920000954 Polyglycolide Polymers 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000011929 di(propylene glycol) methyl ether Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
244000144972 livestock Species 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
241000282887 Suidae Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
229960002903 benzyl benzoate Drugs 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
238000006065 biodegradation reaction Methods 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
229960003086 naltrexone Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229920001169 thermoplastic Polymers 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WGYZMNBUZFHYRX-UHFFFAOYSA-N 1-(1-methoxypropan-2-yloxy)propan-2-ol Chemical compound COCC(C)OCC(C)O WGYZMNBUZFHYRX-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
QBBTZXBTFYKMKT-UHFFFAOYSA-N 2,3-diacetyloxypropyl acetate Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O.CC(=O)OCC(OC(C)=O)COC(C)=O QBBTZXBTFYKMKT-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
MEJYDZQQVZJMPP-UHFFFAOYSA-N 3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound COC1COC2C(OC)COC21 MEJYDZQQVZJMPP-UHFFFAOYSA-N 0.000 description 1
QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000005660 Abamectin Substances 0.000 description 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
241000510960 Oesophagostomum Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000960389 Trichuris suis Species 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
241001447056 Uristes Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
150000008430 aromatic amides Chemical class 0.000 description 1
230000037396 body weight Effects 0.000 description 1
SIXOAUAWLZKQKX-UHFFFAOYSA-N carbonic acid;prop-1-ene Chemical group CC=C.OC(O)=O SIXOAUAWLZKQKX-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940116333 ethyl lactate Drugs 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000012052 hydrophilic carrier Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940113115 polyethylene glycol 200 Drugs 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000010409 thin film Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Compositions Of Macromolecular Compounds (AREA)

PT04076699T 1998-03-19 1999-03-18 Composições poliméricas líquidas para libertação controlada de substâncias bioactivas PT1484033E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7957498P	1998-03-19	1998-03-19
GBGB9815801.7A GB9815801D0 (en)	1998-07-21	1998-07-21	Liquid polymeric compositions for controlled released bioactive substances

Publications (1)

Publication Number	Publication Date
PT1484033E true PT1484033E (pt)	2011-04-21

Family

ID=10835852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT04076699T PT1484033E (pt)	1998-03-19	1999-03-18	Composições poliméricas líquidas para libertação controlada de substâncias bioactivas

Country Status (10)

Country	Link
JP (1)	JP4829405B2 (sr)
AT (1)	ATE499069T1 (sr)
DE (1)	DE69943225D1 (sr)
DK (1)	DK1484033T3 (sr)
GB (1)	GB9815801D0 (sr)
GE (1)	GEP20033012B (sr)
PT (1)	PT1484033E (sr)
RS (1)	RS49840B (sr)
SI (1)	SI1484033T1 (sr)
UA (1)	UA53788C2 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8362086B2 (en) *	2005-08-19	2013-01-29	Merial Limited	Long acting injectable formulations
CN104168886A (zh) *	2012-03-13	2014-11-26	拜耳新西兰有限公司	长效组合物
BR112016005589B8 (pt) *	2013-09-16	2023-04-18	Merck Sharp & Dohme	Composição farmacêutica líquida, e, uso da mesma
KR102101969B1 (ko) *	2017-09-06	2020-04-22	(주)인벤티지랩	목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법

1998
- 1998-07-21 GB GBGB9815801.7A patent/GB9815801D0/en not_active Ceased
1999
- 1999-03-18 PT PT04076699T patent/PT1484033E/pt unknown
- 1999-03-18 DK DK04076699.0T patent/DK1484033T3/da active
- 1999-03-18 SI SI9931052T patent/SI1484033T1/sl unknown
- 1999-03-18 GE GEAP19995598A patent/GEP20033012B/en unknown
- 1999-03-18 DE DE69943225T patent/DE69943225D1/de not_active Expired - Lifetime
- 1999-03-18 JP JP2000536316A patent/JP4829405B2/ja not_active Expired - Lifetime
- 1999-03-18 RS YUP-541/00A patent/RS49840B/sr unknown
- 1999-03-18 UA UA2000105893A patent/UA53788C2/uk unknown
- 1999-03-18 AT AT04076699T patent/ATE499069T1/de active

Also Published As

Publication number	Publication date
GEP20033012B (en)	2003-07-25
ATE499069T1 (de)	2011-03-15
JP2002506797A (ja)	2002-03-05
JP4829405B2 (ja)	2011-12-07
DK1484033T3 (da)	2011-06-14
YU54100A (sh)	2002-11-15
SI1484033T1 (sl)	2011-06-30
DE69943225D1 (de)	2011-04-07
GB9815801D0 (en)	1998-09-16
RS49840B (sr)	2008-08-07
UA53788C2 (uk)	2003-02-17

Publication	Publication Date	Title
EP1484033B1 (en)	2011-02-23	Liquid polymeric compositions for controlled release of bioactive substances
ES2359973T3 (es)	2011-05-30	Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
EP3360538B1 (en)	2023-02-15	Injectable flowable composition comprising buprenorphine
HU228386B1 (hu)	2013-03-28	Javított hatékonyságú leuprolid polimeres bejuttatására szolgáló készítmények
PT2244752E (pt)	2011-12-06	Sistema de distribuição polimérico líquido de baixa viscosidade
MX2014015902A (es)	2015-07-17	Suministro de farmaco biodegradable para las composiciones hidrofobicas.
RS54100B1 (sr)	2015-10-30	Supstanca korisna za lečenje poremećaja metabolizma lipida
RU2394558C2 (ru)	2010-07-20	Формирующийся in situ имплантат для животных
PT1484033E (pt)	2011-04-21	Composições poliméricas líquidas para libertação controlada de substâncias bioactivas
JP2005538052A (ja)	2005-12-15	注射製剤
KR20230052921A (ko)	2023-04-20	지속성 인-시투(in-situ) 형성/겔화 조성물
EP1827377B1 (en)	2008-03-19	In-situ forming implant for animals
DE1467861C (de)	1973-08-30	Verwendung von Organopolysiloxan elastomeren als A^zneimitteltrager in fester Form
MXPA00009143A (en)	2001-07-09	Liquid polymeric compositions for controlled release of bioactive substances
DE1467861A1 (de)	1969-01-30	Verwendung von Organopolysiloxanelastomeren als Arzneimitteltraeger in fester Form mit kontrollierbarer Wirkstofffreigabe
HK1036579B (en)	2007-02-09	Liquid polymeric compositions for controlled release of bioactive substances
DE1467861B (de)		Verwendung von Organopolysiloxanelastomeren als Arzneimittelträger in fester Form